Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort
The number of patients with autoimmune diseases and severe allergies and recipients of transplants increases worldwide. Currently, these patients require lifelong administration of immunomodulatory drugs. Often, these drugs are expensive and show immediate or late-occurring severe side effects. Trea...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2015/471719 |
id |
doaj-8079624eb4bc4424a1abf4a5bf510e0c |
---|---|
record_format |
Article |
spelling |
doaj-8079624eb4bc4424a1abf4a5bf510e0c2020-11-24T20:54:31ZengHindawi LimitedMediators of Inflammation0962-93511466-18612015-01-01201510.1155/2015/471719471719Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative EffortAnja Ten Brinke0Catharien M. U. Hilkens1Nathalie Cools2Edward K. Geissler3James A. Hutchinson4Giovanna Lombardi5Phillip Lord6Birgit Sawitzki7Piotr Trzonkowski8S. Marieke Van Ham9Eva M. Martinez-Caceres10Department of Immunopathology, Sanquin Blood Supply, Division of Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Plesmanlaan 125, 1066 CX Amsterdam, NetherlandsInstitute of Cellular Medicine, Newcastle University, Newcastle NE2 4HH, UKLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp University Hospital (UZA), Wilrijkstraat 10, 2650 Edegem, BelgiumDivision of Experimental Surgery, Department of Surgery, University Hospital Regensburg, Regensburg, 93053 Bavaria, GermanyDivision of Experimental Surgery, Department of Surgery, University Hospital Regensburg, Regensburg, 93053 Bavaria, GermanyDivision of Transplantation Immunology & Mucosal Biology, MRC Centre for Transplantation, King’s College London, Guy’s Hospital, London SE1 9RT, UKSchool of Computing Science, Newcastle University, Newcastle NE2 4HH, UKInstitute of Medical Immunology, Charité University Medicine, Augustenburger Platz 1, 13353 Berlin, GermanyDepartment of Clinical Immunology and Transplantology, Medical University of Gdansk, Debinki 7, 80-952 Gdansk, PolandDepartment of Immunopathology, Sanquin Blood Supply, Division of Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Plesmanlaan 125, 1066 CX Amsterdam, NetherlandsImmunology Division, Germans Trias i Pujol University Hospital, Department of Cellular Biology, Physiology, and Immunology, Universitat Autònoma Barcelona, Campus Can Ruti, 08916 Barcelona, SpainThe number of patients with autoimmune diseases and severe allergies and recipients of transplants increases worldwide. Currently, these patients require lifelong administration of immunomodulatory drugs. Often, these drugs are expensive and show immediate or late-occurring severe side effects. Treatment would be greatly improved by targeting the cause of autoimmunity, that is, loss of tolerance to self-antigens. Accumulating knowledge on immune mechanisms has led to the development of tolerogenic dendritic cells (tolDC), with the specific objective to restrain unwanted immune reactions in the long term. The first clinical trials with tolDC have recently been conducted and more tolDC trials are underway. Although the safety trials have been encouraging, many questions relating to tolDC, for example, cell-manufacturing protocols, administration route, amount and frequency, or mechanism of action, remain to be answered. Aiming to join efforts in translating tolDC and other tolerogenic cellular products (e.g., Tregs and macrophages) to the clinic, a European COST (European Cooperation in Science and Technology) network has been initiated—A FACTT (action to focus and accelerate cell-based tolerance-inducing therapies). A FACTT aims to minimize overlap and maximize comparison of tolDC approaches through establishment of minimum information models and consensus monitoring parameters, ensuring that progress will be in an efficient, safe, and cost-effective way.http://dx.doi.org/10.1155/2015/471719 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anja Ten Brinke Catharien M. U. Hilkens Nathalie Cools Edward K. Geissler James A. Hutchinson Giovanna Lombardi Phillip Lord Birgit Sawitzki Piotr Trzonkowski S. Marieke Van Ham Eva M. Martinez-Caceres |
spellingShingle |
Anja Ten Brinke Catharien M. U. Hilkens Nathalie Cools Edward K. Geissler James A. Hutchinson Giovanna Lombardi Phillip Lord Birgit Sawitzki Piotr Trzonkowski S. Marieke Van Ham Eva M. Martinez-Caceres Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort Mediators of Inflammation |
author_facet |
Anja Ten Brinke Catharien M. U. Hilkens Nathalie Cools Edward K. Geissler James A. Hutchinson Giovanna Lombardi Phillip Lord Birgit Sawitzki Piotr Trzonkowski S. Marieke Van Ham Eva M. Martinez-Caceres |
author_sort |
Anja Ten Brinke |
title |
Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort |
title_short |
Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort |
title_full |
Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort |
title_fullStr |
Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort |
title_full_unstemmed |
Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort |
title_sort |
clinical use of tolerogenic dendritic cells-harmonization approach in european collaborative effort |
publisher |
Hindawi Limited |
series |
Mediators of Inflammation |
issn |
0962-9351 1466-1861 |
publishDate |
2015-01-01 |
description |
The number of patients with autoimmune diseases and severe allergies and recipients of transplants increases worldwide. Currently, these patients require lifelong administration of immunomodulatory drugs. Often, these drugs are expensive and show immediate or late-occurring severe side effects. Treatment would be greatly improved by targeting the cause of autoimmunity, that is, loss of tolerance to self-antigens. Accumulating knowledge on immune mechanisms has led to the development of tolerogenic dendritic cells (tolDC), with the specific objective to restrain unwanted immune reactions in the long term. The first clinical trials with tolDC have recently been conducted and more tolDC trials are underway. Although the safety trials have been encouraging, many questions relating to tolDC, for example, cell-manufacturing protocols, administration route, amount and frequency, or mechanism of action, remain to be answered. Aiming to join efforts in translating tolDC and other tolerogenic cellular products (e.g., Tregs and macrophages) to the clinic, a European COST (European Cooperation in Science and Technology) network has been initiated—A FACTT (action to focus and accelerate cell-based tolerance-inducing therapies). A FACTT aims to minimize overlap and maximize comparison of tolDC approaches through establishment of minimum information models and consensus monitoring parameters, ensuring that progress will be in an efficient, safe, and cost-effective way. |
url |
http://dx.doi.org/10.1155/2015/471719 |
work_keys_str_mv |
AT anjatenbrinke clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort AT catharienmuhilkens clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort AT nathaliecools clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort AT edwardkgeissler clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort AT jamesahutchinson clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort AT giovannalombardi clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort AT philliplord clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort AT birgitsawitzki clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort AT piotrtrzonkowski clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort AT smariekevanham clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort AT evammartinezcaceres clinicaluseoftolerogenicdendriticcellsharmonizationapproachineuropeancollaborativeeffort |
_version_ |
1716794288000466944 |